Physician profile
Kristopher C Schamber
NPI 1942590054
$1,841.40
in general payments reported to CMS, 2019-2025
26 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $197 · 2021: $235 · 2022: $158 · 2023: $268 · 2024: $283 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $841 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $840.62 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $320.54 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $278.30 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $231.02 | 2019-2025 | Breztri |
| Amgen INC. | $121.40 | 2019-2025 | Otezla, Repatha, Prolia |
| Madrigal Pharmaceuticals | $113.84 | 2025 | Rezdiffra |
| Lilly USA, LLC | $109.65 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $76.59 | 2023-2024 | Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.56 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $60.43 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $53.28 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.90 | 2021-2023 | Trintellix |
| Exact Sciences Corporation | $45.14 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $43.01 | 2019-2023 | Vaxneuvance, M-M-R II, Proquad |
| Abbott Laboratories | $37.40 | 2022-2023 | Freestyle Libre 2 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.06 | 2025 | Caplyta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $24.89 | 2020-2021 | |
| Pfizer INC. | $24.21 | 2019 | |
| Grifols USA, LLC | $22.73 | 2019-2020 | |
| Medtronic, INC. | $22.52 | 2024 | Minimed 780g |
| Philips North America LLC | $20.67 | 2024 | (Ck4) Mcot |
| Edwards Lifesciences Corporation | $19.96 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Allergan, INC. | $19.81 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.50 | 2024 | |
| Astellas Pharma US INC | $15.57 | 2020 | |
| Tactile Systems Technology INC | $12.39 | 2019 | |
| Alkermes, INC. | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristopher Schamber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.